SERA PROGNOSTICS, INC. Additional Paid in Capital, Common Stock
SERA PROGNOSTICS, INC. (SERA) had Additional Paid in Capital, Common Stock of $327.53 million as of 2024-12-31, per its 10-K filed 2025-03-19.
Financial Statements › Balance Sheet › Equity, Attributable to Parent › Additional Paid in Capital
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2025-03-19
- 2024-12-31: Additional Paid in Capital, Common Stock $327.53M.
- 2023-12-31: Additional Paid in Capital, Common Stock $317.07M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2024-12-31 | $327.53M 10-K · filed 2025-03-19 |
| 2023-12-31 | $317.07M 10-K · filed 2025-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |